Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.45 |
| ▸ | GRM5 | P41594 | 4/20 | 0.37 |
| ▸ | GCK | P35557 | 8/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3008721 | 0.99 | HPGDS (0.45) | HPGDSGRM5GCKNPC1RAB9A | |
| SCHEMBL3004042 | 0.91 | NPC1 (0.43) | HPGDSGRM5NPC1RAB9AALDH1A1 | |
| SCHEMBL2994602 | 0.91 | GRM5 (0.39) | HPGDSGRM5GCKNPC1RAB9A | |
| SCHEMBL2994480 | 0.91 | HPGDS (0.43) | HPGDSGRM5GCKNPC1RAB9A | |
| SCHEMBL3003372 | 0.90 | GRM5 (0.38) | HPGDSGRM5GCKNPC1RAB9A | |
| SCHEMBL3001763 | 0.90 | HPGDS (0.40) | HPGDSGRM5GCKNPC1RAB9A | |
| SCHEMBL2994085 | 0.89 | GRM5 (0.38) | HPGDSGRM5GCKNPC1RAB9A | |
| SCHEMBL3008822 | 0.89 | GRM5 (0.39) | HPGDSGRM5GCKNPC1RAB9A | |
| SCHEMBL3003089 | 0.88 | GCK (0.39) | HPGDSGRM5GCKNPC1RAB9A | |
| SCHEMBL3007208 | 0.88 | KCNH2 (0.39) | HPGDSGRM5GCKNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190980-A1 | PYRAZINAMIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2010-07-29 | — | — | US | claimed |
| EP-2157090-A1 | PYRAZINAMIDE COMPOUND | Taisho Pharmaceutical Co. Ltd. (JP) | 2010-02-24 | — | — | EP | claimed |
| US-20100190980-A1 | PYRAZINAMIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-2157090-A1 | PYRAZINAMIDE COMPOUND | Taisho Pharmaceutical Co. Ltd. (JP) | 2010-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190980-A1 | PYRAZINAMIDE COMPOUND | KAT8, GK, KCNJ8 | HPGDS 4392/4885GRM5 1751/4885GCK 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.